Seventeen human clinical research of Pycnogenol are examined in the monograph, evaluating the extract’s potential benefits in numerous areas. These include its cardiovascular benefits, such as for example its ability to reduce difficulties associated with chronic venous insufficiency and complications related to thrombosis . Based on the review of clinical and scientific trials, the monograph notes that Pycnogenol offers been shown to have a wide variety of potential applications, including the capability to improve blood sugars control in individuals with type 2 diabetes and improve endothelial function . Current clinical trial data suggest that Pycnogenol also may help decrease edema formation in the low legs, benefit children with interest deficit hyperactivity disorder , be considered a useful adjunct therapy for individuals with asthma, decrease pain connected with menstrual disorders, and improve subjective symptoms of osteoarthritis in the knee.Myocardial infarction was reported in 4.8 percent of patients in the empagliflozin group and 5.4 percent of these in the placebo group, and stroke in 3.5 percent and 3.0 percent of patients, respectively. For the primary and key secondary outcomes, hazard ratios for the comparison between the 10-mg dose of empagliflozin versus placebo and the 25-mg dose versus placebo were virtually identical to those in the pooled analysis, but the individual dose results weren’t significant, owing to small amounts of outcome events in the average person groups .